Clinical Trials Logo
  1. Home
  2. Glaucoma
  3. NCT03270761
  4. Details
NCT03270761 Clinical Trial

Zhongshan Iridocorneal Endothelial Syndrome Study (ICEs)

Glaucoma Clinical Trial

Official title:
A Multi-center Study on Iridocorneal Endothelial (ICE) Syndrome in China

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03270761
Other study ID # 2017KYPJ071
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 10, 2017
Est. completion date December 31, 2019

Study information
Verified date June 2021
Source Sun Yat-sen University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

This is a multi-center study to report the demographic profile, clinical features, and management in patients with Iridocorneal endothelial (ICE) syndrome in China.

Recruitment information / eligibility
Status Completed
Enrollment 98
Est. completion date December 31, 2019
Est. primary completion date December 12, 2019
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Clinical diagnosis of ICE syndrome; - Those willing to sign the informed consent. Exclusion Criteria: - Patients who don't sign the informed consent or abide by the study procedure.

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
China Zhongshan Ophthalmic Center Guangzhou Guangdong

Sponsors (2)
Lead Sponsor Collaborator
Sun Yat-sen University ICE study group

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary Management in patients with Iridocorneal endothelial (ICE) syndrome Record the number of medication treating corneal edema or glaucoma, and surgery (anti-glaucoma surgery, keratoplasty) through study completion, an average of 1 year
Secondary Demographic profile of patients Range of age, gender 1 day
See also
  Status Clinical Trial Phase
Recruiting NCT06000865 - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE N/A
Recruiting NCT06278597 - Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03274024 - The Asia Primary Tube Versus Trab (TVT) Study N/A
Completed NCT04552964 - Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma N/A
Recruiting NCT01957267 - Functional and Structural Imaging for Glaucoma
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Completed NCT04020705 - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma N/A
Completed NCT03150160 - Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Phase 4
Not yet recruiting NCT05581498 - Glaucoma Exercise as Medicine Study (GEMS). N/A
Recruiting NCT02921568 - Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes N/A
Active, not recruiting NCT02901730 - Clinical Study of LPI With Different Laser Wavelengths N/A
Completed NCT02955849 - A Trial of China Laser and Surgery Study Glaucoma in Rural China Early Phase 1
Recruiting NCT02554214 - Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device N/A
Recruiting NCT02471105 - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Phase 4
Active, not recruiting NCT02390284 - Stop Retinal Ganglion Cell Dysfunction Study Phase 3
Completed NCT02628223 - 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma N/A
Completed NCT02520674 - Glaucoma Screening With Smartphone Ophthalmology N/A
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Completed NCT02246764 - Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Phase 3